Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review

the Japan Academic Consortium of Kidney Transplantation (JACK) Investigators

研究成果: ジャーナルへの寄稿記事

抄録

Background: The safety of kidney transplantation (KT) for end-stage kidney disease (ESKD) after haematopoietic stem cell transplantation (HSCT) for haematological disease has not been investigated thoroughly. Methods: In this retrospective multicentre study, we investigated the clinical courses of six ESKD patients that received KT after HSCT for various haematological diseases. Data for six such patients were obtained from three institutions in our consortium. Results: Two patients with chronic myeloid leukaemia, one with refractory aplastic anaemia and another one with acute lymphocytic leukaemia received bone marrow transplantation. One patients with acute lymphocytic leukaemia received umbilical cord blood transplantation, and one with mantle cell lymphoma received peripheral blood stem cell transplantation. The patients developed ESKD at a median of 133 months after HSCT. Two patients who received KT and HSCT from the same donor were temporarily treated with immunosuppressive drugs. The other patients received KT and HSCT from different donors and were treated with antibody induction using our standard regimens. For one patient with ABO-incompatible transplantation, we added rituximab, splenectomy, and plasmapheresis. In the observational period at a median of 51 months after KT, only one patient experienced acute T-cell-mediated rejection. Four patients underwent hospitalization because of infection and fully recovered. No patient experienced recurrence of their original haematological disease. All patients survived throughout the observational periods, and graft functions were preserved. Conclusions: Despite the high infection frequency, survival rates and graft functions were extremely good in patients compared with previous studies. Therefore, current management contributed to favourable outcomes of these patients.

元の言語英語
ページ(範囲)561-568
ページ数8
ジャーナルClinical and Experimental Nephrology
23
発行部数4
DOI
出版物ステータス出版済み - 4 2 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Kidney Transplantation
Chronic Kidney Failure
Therapeutics
Hematologic Diseases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplantation
Tissue Donors
Refractory Anemia
Transplants
Mantle-Cell Lymphoma
Peripheral Blood Stem Cell Transplantation
Plasmapheresis
Aplastic Anemia
Splenectomy
Immunosuppressive Agents
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Infection
Bone Marrow Transplantation
Fetal Blood

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

これを引用

Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation : case series and literature review. / the Japan Academic Consortium of Kidney Transplantation (JACK) Investigators.

:: Clinical and Experimental Nephrology, 巻 23, 番号 4, 02.04.2019, p. 561-568.

研究成果: ジャーナルへの寄稿記事

the Japan Academic Consortium of Kidney Transplantation (JACK) Investigators. / Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation : case series and literature review. :: Clinical and Experimental Nephrology. 2019 ; 巻 23, 番号 4. pp. 561-568.
@article{56e5fa5aca8944429e869b5fcb79a454,
title = "Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review",
abstract = "Background: The safety of kidney transplantation (KT) for end-stage kidney disease (ESKD) after haematopoietic stem cell transplantation (HSCT) for haematological disease has not been investigated thoroughly. Methods: In this retrospective multicentre study, we investigated the clinical courses of six ESKD patients that received KT after HSCT for various haematological diseases. Data for six such patients were obtained from three institutions in our consortium. Results: Two patients with chronic myeloid leukaemia, one with refractory aplastic anaemia and another one with acute lymphocytic leukaemia received bone marrow transplantation. One patients with acute lymphocytic leukaemia received umbilical cord blood transplantation, and one with mantle cell lymphoma received peripheral blood stem cell transplantation. The patients developed ESKD at a median of 133 months after HSCT. Two patients who received KT and HSCT from the same donor were temporarily treated with immunosuppressive drugs. The other patients received KT and HSCT from different donors and were treated with antibody induction using our standard regimens. For one patient with ABO-incompatible transplantation, we added rituximab, splenectomy, and plasmapheresis. In the observational period at a median of 51 months after KT, only one patient experienced acute T-cell-mediated rejection. Four patients underwent hospitalization because of infection and fully recovered. No patient experienced recurrence of their original haematological disease. All patients survived throughout the observational periods, and graft functions were preserved. Conclusions: Despite the high infection frequency, survival rates and graft functions were extremely good in patients compared with previous studies. Therefore, current management contributed to favourable outcomes of these patients.",
author = "{the Japan Academic Consortium of Kidney Transplantation (JACK) Investigators} and akihiro tsuchimoto and Kosuke Masutani and Kazuya Omoto and Masayoshi Okumi and Yasuhiro Okabe and Takehiro Nishiki and Morihito Ota and Toshiaki Nakano and Kazuhiko Tsuruya and Takanari Kitazono and Masafumi Nakamura and Hideki Ishida and Kazunari Tanabe and Kazunari Tanabe and Masashi Inui and Tomokazu Shimizu and Toshihito Hirai and Daisuke Toki and Kohei Unagami and Hiroshi Toma and Hiroki Shirakawa and Atsuchi Doi and Keizo Kaku and Kei Kurihara and Ota Morihito",
year = "2019",
month = "4",
day = "2",
doi = "10.1007/s10157-018-1672-1",
language = "English",
volume = "23",
pages = "561--568",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation

T2 - case series and literature review

AU - the Japan Academic Consortium of Kidney Transplantation (JACK) Investigators

AU - tsuchimoto, akihiro

AU - Masutani, Kosuke

AU - Omoto, Kazuya

AU - Okumi, Masayoshi

AU - Okabe, Yasuhiro

AU - Nishiki, Takehiro

AU - Ota, Morihito

AU - Nakano, Toshiaki

AU - Tsuruya, Kazuhiko

AU - Kitazono, Takanari

AU - Nakamura, Masafumi

AU - Ishida, Hideki

AU - Tanabe, Kazunari

AU - Tanabe, Kazunari

AU - Inui, Masashi

AU - Shimizu, Tomokazu

AU - Hirai, Toshihito

AU - Toki, Daisuke

AU - Unagami, Kohei

AU - Toma, Hiroshi

AU - Shirakawa, Hiroki

AU - Doi, Atsuchi

AU - Kaku, Keizo

AU - Kurihara, Kei

AU - Morihito, Ota

PY - 2019/4/2

Y1 - 2019/4/2

N2 - Background: The safety of kidney transplantation (KT) for end-stage kidney disease (ESKD) after haematopoietic stem cell transplantation (HSCT) for haematological disease has not been investigated thoroughly. Methods: In this retrospective multicentre study, we investigated the clinical courses of six ESKD patients that received KT after HSCT for various haematological diseases. Data for six such patients were obtained from three institutions in our consortium. Results: Two patients with chronic myeloid leukaemia, one with refractory aplastic anaemia and another one with acute lymphocytic leukaemia received bone marrow transplantation. One patients with acute lymphocytic leukaemia received umbilical cord blood transplantation, and one with mantle cell lymphoma received peripheral blood stem cell transplantation. The patients developed ESKD at a median of 133 months after HSCT. Two patients who received KT and HSCT from the same donor were temporarily treated with immunosuppressive drugs. The other patients received KT and HSCT from different donors and were treated with antibody induction using our standard regimens. For one patient with ABO-incompatible transplantation, we added rituximab, splenectomy, and plasmapheresis. In the observational period at a median of 51 months after KT, only one patient experienced acute T-cell-mediated rejection. Four patients underwent hospitalization because of infection and fully recovered. No patient experienced recurrence of their original haematological disease. All patients survived throughout the observational periods, and graft functions were preserved. Conclusions: Despite the high infection frequency, survival rates and graft functions were extremely good in patients compared with previous studies. Therefore, current management contributed to favourable outcomes of these patients.

AB - Background: The safety of kidney transplantation (KT) for end-stage kidney disease (ESKD) after haematopoietic stem cell transplantation (HSCT) for haematological disease has not been investigated thoroughly. Methods: In this retrospective multicentre study, we investigated the clinical courses of six ESKD patients that received KT after HSCT for various haematological diseases. Data for six such patients were obtained from three institutions in our consortium. Results: Two patients with chronic myeloid leukaemia, one with refractory aplastic anaemia and another one with acute lymphocytic leukaemia received bone marrow transplantation. One patients with acute lymphocytic leukaemia received umbilical cord blood transplantation, and one with mantle cell lymphoma received peripheral blood stem cell transplantation. The patients developed ESKD at a median of 133 months after HSCT. Two patients who received KT and HSCT from the same donor were temporarily treated with immunosuppressive drugs. The other patients received KT and HSCT from different donors and were treated with antibody induction using our standard regimens. For one patient with ABO-incompatible transplantation, we added rituximab, splenectomy, and plasmapheresis. In the observational period at a median of 51 months after KT, only one patient experienced acute T-cell-mediated rejection. Four patients underwent hospitalization because of infection and fully recovered. No patient experienced recurrence of their original haematological disease. All patients survived throughout the observational periods, and graft functions were preserved. Conclusions: Despite the high infection frequency, survival rates and graft functions were extremely good in patients compared with previous studies. Therefore, current management contributed to favourable outcomes of these patients.

UR - http://www.scopus.com/inward/record.url?scp=85059012564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059012564&partnerID=8YFLogxK

U2 - 10.1007/s10157-018-1672-1

DO - 10.1007/s10157-018-1672-1

M3 - Article

VL - 23

SP - 561

EP - 568

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 4

ER -